Get the Stockscreener App
3.87
1.28%
-0.05
Orchestra Biomed Holdings Inc stock is traded at $3.87, with a volume of 57,376.
It is down -1.28% in the last 24 hours and down -4.21% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$3.92
Open:
$3.87
24h Volume:
57,376
Relative Volume:
0.25
Market Cap:
$217.48M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-2.58
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
+1.04%
1M Performance:
-4.21%
6M Performance:
+51.76%
1Y Performance:
-18.01%
1-Day Range:
$3.8516
$3.98
1-Week Range:
$3.76
$4.1199
52-Week Range:
$2.20
$5.424
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
3.8516 | 221.34M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.68 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.21 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
831.08 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.67 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.39 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Market Leaders: Will Orchestra BioMed Holdings Inc benefit from AI trendsJuly 2025 Analyst Calls & Precise Buy Zone Identification - baoquankhu1.vn
Will Orchestra BioMed Holdings Inc. benefit from geopolitical trendsJuly 2025 Decliners & Real-Time Volume Analysis Alerts - mfd.ru
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed (NASDAQ:OBIO) Trading 4.2% HigherHere's What Happened - MarketBeat
Orchestra BioMed Grants Inducement Stock Options to Nine New Employees - MyChesCo
Earnings Recap: Will MITTPRA stock hit new highs in YEARQuarterly Earnings Report & Expert Approved Trade Ideas - baoquankhu1.vn
Orchestra BioMed announces inducement grants - Medical Buyer
What is Orchestra BioMed Holdings Inc. s P E ratio telling usJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - mfd.ru
Orchestra BioMed Adopts 2026 Performance-Driven Executive Compensation Plan - TipRanks
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Orchestra BioMed Grants Stock Options to New Employees as Part of 2025 Inducement Plan - Quiver Quantitative
Does Orchestra BioMed Holdings Inc. outperform in volatile markets2025 Price Targets & Growth Focused Investment Plans - mfd.ru
Targets Report: How Orchestra BioMed Holdings Inc. stock performs after earningsJuly 2025 Outlook & AI Forecasted Stock Moves - mfd.ru
How sensitive is Orchestra BioMed Holdings Inc. to inflation2025 Trade Ideas & Fast Exit/Entry Strategy Plans - mfd.ru
MACD Signal: What is Orchestra BioMed Holdings Incs 5 year growth outlookEntry Point & Reliable Price Breakout Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), LENZ Therapeutics (LENZ) and Amgen (AMGN) - The Globe and Mail
Short Covering: Does Orchestra BioMed Holdings Inc outperform in volatile markets2025 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Guidance Update: Does Orchestra BioMed Holdings Inc stock benefit from AI growth2025 Winners & Losers & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Risk Report: Is Rafael Holdings Inc affected by consumer sentimentShare Buyback & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17% - Yahoo Finance
Aug Setups: What is Orchestra BioMed Holdings Inc. s 5 year growth outlookWeekly Trading Summary & Intraday High Probability Setup Alerts - baoquankhu1.vn
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting - MSN
AMH Equity Ltd Buys New Position in Orchestra BioMed Holdings, Inc. $OBIO - Defense World
Orchestra BioMed (NASDAQ:OBIO) versus Prima BioMed (NASDAQ:IMMP) Critical Analysis - Defense World
Retail Trends: Does PNTG have strong fundamentalsQuarterly Trade Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Support Test: Is Orchestra BioMed Holdings Inc stock a contrarian buyQuarterly Performance Summary & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Retail Trends: Should value investors consider Orchestra BioMed Holdings Inc - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
Haemonetics (HAE) Acquisition of Vivasure Boosts Orchestra BioMed's Finances - GuruFocus
Orchestra BioMed Holdings, Inc. to Receive Proceeds from Vivasure Acquisition - TradingView
Early bet on vessel-closure patch could bring this firm $21M windfall - Stock Titan
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics - Sahm
Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts - Benzinga
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) market cap touched US$251m last week, benefiting both retail investors who own 41% as well as institutions - Sahm
Can Orchestra BioMed Holdings Inc. stock continue upward trendForecast Cut & Long-Term Growth Portfolio Plans - Улправда
Can Orchestra BioMed Holdings Inc. stock rebound after recent weakness2025 Historical Comparison & Weekly Watchlist of Top Performers - ulpravda.ru
Published on: 2026-01-09 01:26:31 - Улправда
Is Orchestra BioMed Holdings Inc. stock a dividend growth opportunityJuly 2025 Update & Daily Chart Pattern Signal Reports - ulpravda.ru
Is Orchestra BioMed Holdings Inc. stock a safe buy before earningsBreakout Watch & Daily Profit Focused Stock Screening - Улправда
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Orchestra BioMed (NASDAQ:OBIO) Shares Up 0.2% – Here’s Why - Defense World
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs - Insider Monkey
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra BioMed Grants New Hire Stock Options as Clinical Programs Advance - MSN
What drives Orchestra BioMed Holdings Inc stock priceEarnings Beat Highlights & Receive Monthly Expert Trading Blueprints - earlytimes.in
Orchestra BioMed Holdings, Inc.(NasdaqGM: OBIO) added to NASDAQ Biotechnology Index - marketscreener.com
Why Orchestra BioMed Holdings Inc. stock is in analyst buy zone2025 Top Decliners & Low Risk High Win Rate Stock Picks - Улправда
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates - MSN
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):